Inhibition of renin: An updated review of the development of renin inhibitors

Current Opinion in Investigational Drugs

Volumn 8, Issue 9, 2007, Pages 750-757

  Li, Y C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Aliskiren; Renin; Renin inhibitor; Renin angiotensin system vitamin D analog

Indexed keywords

ALDOSTERONE; ALFACALCIDOL; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CGP 38560; CIPROKIREN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXERCALCIFEROL; ENALAPRIL; ENALAPRILAT; ENALKIREN; IRBESARTAN; N BENZYLOXYCARBONYLARGINYLARGINYLPROLYLPHENYLALANYLHISTIDYLSTATINYL ISOLEUCYLHISTIDYL (NEPSILON BUTYLOXYCARBONYLLYSINE) METHYL ESTER; N BENZYLOXYCARBONYLARGINYLARGINYLPROLYLPHENYLALANYLHISTIDYLSTATINYLISOLEUCYLHISTIDYL (NEPSILON BUTYLOXYCARBONYLLYSINE) METHYL ESTER; PARICALCITOL; PLACEBO; R 3 36 16; REMIKIREN; RENIN; RENIN INHIBITOR; UNCLASSIFIED DRUG; VALSARTAN; ZANKIREN;

CLINICAL TRIAL; DOG; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; GENE EXPRESSION; HUMAN; HYPERTENSION; MOUSE STRAIN; NONHUMAN; PLASMA RENIN ACTIVITY; RANDOMIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRANSGENIC RAT;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBODIES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG DESIGN; ENZYME INHIBITORS; FUMARATES; HUMANS; HYPERTENSION; MOLECULAR STRUCTURE; PEPTIDES; RECEPTORS, CELL SURFACE; RENIN; RENIN-ANGIOTENSIN SYSTEM; VACUOLAR PROTON-TRANSLOCATING ATPASES; VITAMIN D;

EID: 34548362053     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 42(6):1206-1252.
2. Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP: The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med (1957) 106(3):439-453.
3. Moffett DF, Moffett SB, Schauf CL (Eds): Human Physiology. Foundation and Frontiers. 2nd Edition. WMC Brown Publishers, Dubuque, Iowa, USA (1993).
4. Ballermann BJ, Zeidel ML, Gunning ME, Brenner BM: Vasoactive peptides and the kidney. In: The Kidney. 4th Edition. Brenner BM, Rector FC (Eds), WB Saunders Company, Philadelphia, PA, USA (1991):510-583.
5. Inagami T: The renin-angiotensin system. Essays Biochem (1994) 28:147-164.
6. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG: Angiotensin receptors: Signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol (2001) 281(6): H2337-H2365.
7. Vander AJ, Geelhoed GW: Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med (1965) 120(2):399-403.
8. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, Goto S, Imaizumi K, Hisada Y, Otsuka A, Uchida H et al: Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem (1995) 270(32):18719-18722.
9. Shricker K, Holmer S, Kramer BK, Riegger GA, Kurtz A: The role of angiotensin II in the feedback control of renin gene expression. Pflugers Arch (1997) 434(2):166-172.
10. August P: Initial treatment of hypertension. N Engl J Med (2003) 348(7):610-617.
11. Cheung BM: Blockade of the renin-angiotensin system. Hong Kong Med J (2002) 8(3):185-191.
12. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem (1990) 265(36):22348-22357.
13. Padmanabhan N, Jardine AG, McGrath JC, Connell JM: Angiotensin- converting enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation (1999) 99(22):2914-2920.
14. Tom B, Dendorfer A, Danser AH: Bradykinin, angiotensin-(1-7), and ACE inhibitors: How do they interact? Int J Biochem Cell Biol (2003) 35(6):792-801.
15. Reudelhuber TL: The renin-angiotensin system: Peptides and enzymes beyond angiotensin II. Curr Opin Nephrol Hypertens (2005) 14(2):155-159.
16. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B: Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol (1993) 33(1):40-45.
17. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, Sanz G: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J (2000) 21(1):53-57.
18. Burton J, Quinn T: The amino-acid residues on the C-terminal side of the cleavage site of angiotensinogen influence the species specificity of reaction with renin. Biochim Biophys Acta (1988) 952(1):8-12.
19. Hatae T, Takimoto E, Murakami K, Fukamizu A: Comparative studies on species-specific reactivity between renin and angiotensinogen. Mol Cell Biochem (1994) 131(1):43-47.
20. Yang G, Merrill DC, Thompson MW, Robillard JE, Sigmund CD: Functional expression of the human angiotensinogen gene in transgenic mice. J Biol Chem (1994) 269(51):32497-32502.
21. Danser AH, Deinum J: Renin, prorenin and the putative (pro)renin receptor. Hypertension (2005) 46(5):1069-1076.
22. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, Ishida Y, Nakamura Y, Murakami K: Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem (2003) 278(25):22217-22222.
23. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH et al: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest (2004) 114(8):1128-1135.
24. Mullins JJ, Peters J, Ganten D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature (1990) 344(6266):541-544.
25. Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T: Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med (2002) 252(5): 430-439.
26. Kehoe B, Keeton GR, Hill C: Elevated plasma renin activity associated with renal dysfunction. Nephron (1986) 44(1):51-57.
27. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL: A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int (1998) 54(2):343-352.
28. Chiarelli F, Pomilio M, De Luca FA, Vecchiet J, Verrotti A: Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol (2001) 16(2):116-120.
29. Deinum J, Ronn B, Mathiesen E, Derkx FH, Hop WC, Schalekamp MA: Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia (1999) 42(8):1006-1010.
30. Davies L, Fulcher GR, Atkins A, Frumar K, Monaghan J, Stokes G, Clifton-Bligh P, McElduff A, Robinson B, Stiel J, Twigg S, Wilmshurst E: The relationship of prorenin values to microvascular complications in patients with insulin-dependent diabetes mellitus. J Diabetes Complicat (1999) 13(1):45-51.
31. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M: Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med (1985) 312(22):1412- 1417.
32. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J: Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest (1996) 98(9):1966- 1970. • This paper reports that overexpression of prorenin in animals causes vascular damage independent of Ang II and chronic hypertension.
33. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest (2002) 109(11):1417-1427. •• This paper describes the first cloning of a prorenin/renin receptor that not only enhanced the enzymatic activity of renin but also directly mediated intracellular signaling of prorenin and renin, providing a mechanistic explanation for Ang II-independent activities of renin and prorenin.
34. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W: Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int (2006) 69(1):105-113. • This study provided evidence that renin directly stimulated TGFβ in mesangial cells via a receptor-mediated mechanism, suggesting an Ang II-independent role of renin in kidney damage.
35. Dzau VJ, Kopelman RI, Barger AC, Haber E: Renin-specific antibody for study of cardiovascular homeostasis. Science (1980) 207(4435):1091-1093. • This early study demonstrated that inhibition of renin by antibody reduced plasma renin activity and BP.
36. Wood JM, Heusser C, Gulati N, Forgiarini P, Hofbauer KG: Monoclonal antibodies against human renin. Blood pressure effects in the marmoset. Hypertension (1986) 8(7):600-605.
37. Neisius D, Wood JM, Hofbauer KG: Renal vasodilatation after inhibition of renin or converting enzyme in marmoset. Am J Physiol (1986) 251(5 Pt 2):H897-H902.
38. Kokubu T, Ueda E, Fujimoto S, Hiwada K, Kato A: Peptide inhibitors of the renin-angiotensin system. Nature (1968) 217(5127):456-457.
39. Wood JM, Stanton JL, Hofbauer KG: Inhibitors of renin as potential therapeutic agents. J Enzyme Inhib (1987) 1(3):169-185.
40. Burton J, Poulsen K, Haber E: Competitive inhibitors of renin. Inhibitors effective at physiological pH. Biochemistry (1975) 14(17):3892-3898.
41. Burton J, Cody RJ Jr, Herd JA, Haber E: Specific inhibition of renin by an angiotensinogen analog: Studies in sodium depletion and renin-dependent hypertension. Proc Natl Acad Sci USA (1980) 77(9):5476-5479.
42. Boger J, Lohr NS, Ulm EH, Poe M, Blaine EH, Fanelli GM, Lin TY, Payne LS, Schorn TW, LaMont BI, Vassil TC et al: Novel renin inhibitors containing the amino acid statine. Nature (1983) 303(5912):81- 84. • This paper describes the incorporation of statine into peptide analogs to generate highly potent renin inhibitors.
43. Wood JM, Gulati N, Forgiarini P, Fuhrer W, Hofbauer KG: Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension (1985) 7(5):797-803.
44. Wood JM, Criscione L, de Gasparo M, Buhlmayer P, Rueger H, Stanton JL, Jupp RA, Kay J: CGP 38 560: Orally active, low-molecular-weight renin inhibitor with high potency and specificity. J Cardiovasc Pharmacol (1989) 14(2):221-226. • This representative paper describes low-molecular weight renin inhibitors as highly potent and orally active compounds, with low oral bioavailability.
45. Delabays A, Nussberger J, Porchet M, Waeber B, Hoyos P, Boger R, Glassman H, Kleinert HD, Luther R, Brunner HR: Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension (1989) 13(6 Pt 2):941-947.
46. Camenzind E, Nussberger J, Juillerat L, Munafo A, Fischli W, Coassolo P, van Brummelen P, Kleinbloesem CH, Waeber B, Brunner HR: Effect of the renin response during renin inhibition: Oral Ro 42-5892 in normal humans. J Cardiovasc Pharmacol (1991) 18(3):299-307.
47. Kobrin I, Viskoper RJ, Laszt A, Bock J, Weber C, Charlon V: Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens (1993) 6(5 Pt 1):349-356.
48. Fischli W, Clozel JP, Breu V, Buchmann S, Mathews S, Stadler H, Vieira E, Wostl W: Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. Hypertension (1994) 24(2):163-169.
49. Menard J, Boger RS, Moyse DM, Guyene TT, Glassman HN, Kleinert HD: Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation (1995) 91(2):330-338.
50. Abbott Laboratories: Drug development pipeline: Zankiren. Company Communication (2000): August 03.
51. Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM, Grutter MG: Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol (2000) 7(7):493-504. • The first paper to describe the design and synthesis of a novel class of nonpeptide renin inhibitors based on the X-ray crystal structure of the renininhibitor complex.
52. Novartis AG: Tekturna® - the first new type of high blood pressure medicine in more than a decade - receives its first approval in the US. Press Release (2007): March 06.
53. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, Ruger H, Goschke R, Stutz S, Fuhrer W, Schilling W et al: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun (2003) 308(4):698-705. •• This was the first comprehensive report of aliskiren, describing its chemical structure, interaction with the renin active site, and potent activity to suppress plasma renin activity and reduce BP in humans through oral administration.
54. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL: Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens (2005) 23(2):417-426.
55. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): Comparison with enalapril. Hypertension (2002) 39(1):E1-E8. • This proof-of-concept study provided comprehensive information concerning aliskiren's pharmacological properties in humans in a dose- and time-dependent manner. It showed that orally administered aliskiren effectively suppressed plasma renin activity and Ang I and II, and dramatically increased plasma renin concentration.
56. Stanton A, Jensen C, Nussberger J, O'Brien E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 42(6):1137-1143.
57. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 111(8):1012-1018. • This multicenter phase II clinical trial examined the antihypertensive efficacy and tolerability of aliskiren compared with irbesartan in hypertensive patients.
58. 1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol (2004) 15(12):3126-3133.
59. Pan L, Gross KW: Transcriptional regulation of renin: An update. Hypertension (2005) 45(1):3-8.
60. 3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest (2002) 110(2):229-238. •• This study was the first demonstration that calcitriol functions as a negative renin regulator to suppress renin expression in mice and cell cultures, and provided a molecular basis to explore the potential of vitamin D analogs as renin biosynthesis inhibitors.
61. Kong J, Li YC: Effect of Ang II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Am J Physiol Regul Integr Comp Physiol (2003) 285(1):R255-R261.
62. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC: Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab (2005) 288(1):E125-E132.
63. Kristal-Boneh E, Froom P, Harari G, Ribak J: Association of calcitriol and blood pressure in normotensive men. Hypertension (1997) 30(5):1289-1294.
64. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S: Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens (1995) 8(9):894-901.
65. Resnick LM, Muller FB, Laragh JH: Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med (1986) 105(5):649-654.
66. Rostand SG: Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension (1997) 30(2 Pt 1):150-156.
67. He J, Klag MJ, Wu Z, Whelton PK: Stroke in the People's Republic of China. I. Geographic variations in incidence and risk factors. Stroke (1995) 26(12):2222-2227.
68. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM: Ultraviolet B and blood pressure. Lancet (1998) 352(9129):709-710.
69. Lind L, Wengle B, Wide L, Ljunghall S: Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertens (1989) 2(1):20-25.
70. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C: Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab (2001) 86(4):1633-1637.
71. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis (1999) 33(1):73-81.
72. 3 users in a haemodialysis population. Nephrol Dial Transplant (2004) 19(1):179-184.
73. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 349(5):446-456.
74. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol (2005) 16(4):1115- 1125.
75. Levin A, Li YC: Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease? Kidney Int (2005) 68(5):1973-1981.
76. Achinger SG, Ayus JC: The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int Suppl (2005) 95: S37-S42.
77. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J: Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol (2004) 89-90(1-5):387- 392.
78. 3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol (2005) 96(1):59-66. • This exploratory study demonstrated that vitamin D analogs inhibited renin expression in mice without invoking severe hypercalcemia.
79. Fisher ND, Hollenberg NK: Renin inhibition: What are the therapeutic opportunities? J Am Soc Nephrol (2005) 16(3):592-599.